Wire · opportunities
Psilocybin proves promising in neuropathic pain mouse study
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 September 2026 · Fusion42 review
A recent study found that psilocybin administered before chemotherapy prevented neuropathic pain development in mice, with effects lasting up to 8 months. Researchers are now initiating a phase 2 trial to assess psilocybin's efficacy in preventing chemotherapy-induced peripheral neuropathy in cancer patients.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can explore early opportunities in psychedelic drug development beyond mental health as psilocybin shows real promise for chemotherapy-induced neuropathy. This opens new therapeutic niches where psychedelics move from mental wellness to serious physical health treatment.
◆ Coverage
1 source · 3 Sep 2026
◆ Related on Wire
◆ Topics